Document 0840
 DOCN  M9440840
 TI    Passively transferred antibodies directed against conserved regions of
       SIV envelope protect macaques from SIV infection.
 DT    9404
 AU    Lewis MG; Elkins WR; McCutchan FE; Benveniste RE; Lai CY; Montefiori DC;
       Burke DS; Eddy GA; Shafferman A; Henry M. Jackson Foundation Research
       Laboratory, Rockville, MD; 20852.
 SO    Vaccine. 1993 Oct;11(13):1347-55. Unique Identifier : AIDSLINE
       MED/94127087
 AB    Inactivated plasma collected from either SIV-infected or
       peptide-vaccinated macaques was transferred into 17 naive rhesus
       monkeys. Two additional macaques received normal plasma and served as
       controls. Following transfer all 19 monkeys were inoculated with SIV.
       While the controls became infected and were virus-isolation-positive, 3
       of 6 recipients of SIV peptide vaccine plasma and 9 of 11 recipients of
       SIV-infected monkey plasma were protected. None of the 12 protected
       animals became virus-isolation-positive or seroconverted within 100 days
       of follow-up. One, however was SIV-PCR-positive. All 12 protected
       animals were rechallenged 100 days after the initial inoculation; 8
       became infected and yielded virus as expected, but 4 remained
       uninfected. One of the latter was the SIV-PCR-positive monkey mentioned
       above, suggesting that cryptic SIV infection may be of significance in
       immunological protection. The results demonstrate that envelope
       anti-peptide antibodies have similar protective potential in vivo as
       antibodies directed to the whole virus. In vitro neutralization
       competition assays performed with sera from vaccinated macaques in the
       presence of the free peptides suggest that of the four conserved
       envelope peptides of the vaccine, the two originating from gp41 rather
       than the two from gp120 are responsible for inducing the neutralizing
       anti-syncytial activity.
 DE    Amino Acid Sequence  Animal  Antibodies, Viral/*THERAPEUTIC USE
       Antibody Specificity  Antibody-Dependent Cell Cytotoxicity/IMMUNOLOGY
       Antigenic Determinants/IMMUNOLOGY  Base Sequence  Complement/IMMUNOLOGY
       DNA, Viral/BLOOD  HIV Envelope Protein gp120/IMMUNOLOGY  HIV Envelope
       Protein gp41/IMMUNOLOGY  *Immunotherapy, Adoptive  Lymph Nodes/CHEMISTRY
       Lymphocytes/CHEMISTRY  Macaca mulatta  Molecular Sequence Data  Peptide
       Fragments/IMMUNOLOGY  Simian Acquired Immunodeficiency
       Syndrome/BLOOD/*PREVENTION &  CONTROL  Support, U.S. Gov't, Non-P.H.S.
       SIV/GENETICS/*IMMUNOLOGY  Viral Envelope Proteins/*IMMUNOLOGY  JOURNAL
       ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).